Joshua Lukenbill, DO is a medical oncology and hematology physician with Mission Cancer + Blood. Dr. Hughes graduated from The University of Iowa with a dual BS degree in biochemistry and psychology. He went to A.T. Still University (Kirksville, MO) for Medical School, followed by an Internal Medicine residency at The Cleveland Clinic and a Hematology/Oncology fellowship also at The Cleveland Clinic.

Dr. Lukenbill is highly rated in 89 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Multiple Myeloma, Glioma, Bone Marrow Aspiration, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 6 peer reviewed articles and participating in 122 clinical trials. Dr. Lukenbill is currently accepting new patients.

Specialties

Hematology Oncology

Licenses

Internal Medicine in IA

Hospital Affiliations

St Anthony Regional Hospital & Nursing Home

University Of Iowa Hospital & Clinics

Unitypoint Health - Des Moines Iowa Methodist Medi

Stewart Memorial Community Hospital

Mercyone Des Moines Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Anthem BCBS

Blue Cross Blue Shield

Change Healthcare

OTHER MEDICARE
OTHER MEDICARE PART D

Cigna

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Health Net

Accepted plan types not found. Please verify directly with the provider.

HealthPartners

Highmark

Humana

HMO
INDEMNITY
POS
PPO

Independent Health

Managed Medicaid

OTHER MANAGED MEDICAID

Medica

Medicaid

OTHER MEDICAID
STATE MEDICAID

Medicare

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE PART D

Northern Plains Alliance

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE PDP

Oscar

TeamCare

OTHER COMMERCIAL

UnitedHealthcare

Walgreens

MEDICARE DISCOUNT CARD
MEDICARE PDP
OTHER MEDICARE

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

Wellmark

View 17 Less Insurance Carriers -

Locations

Mission Blood + Cancer
411 Laurel St., Suite A300, Des Moines, IA 50314

Call: 515-247-3970

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

119 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

Enrollment Status: Recruiting

Publish Date: September 08, 2026

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium

Study Phase: Phase 3

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Enrollment Status: Recruiting

Publish Date: September 04, 2026

Intervention Type: Drug, Procedure

Study Drug: Olaparib

Study Phase: Phase 2

Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study

Enrollment Status: Recruiting

Publish Date: September 04, 2026

Intervention Type: Procedure, Biological, Drug, Other

Study Drugs: Obinutuzumab, Venetoclax

Study Phase: Phase 3

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Enrollment Status: Active_not_recruiting

Publish Date: September 08, 2026

Intervention Type: Drug, Biological

Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium

Study Phase: Phase 3

Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 08, 2026

Intervention Type: Other, Procedure, Drug, Biological

Study Phase: Phase 3

Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: September 04, 2026

Intervention Type: Procedure, Biological, Drug

Study Drugs: Lenalidomide, Methotrexate, Nivolumab, Rituximab

Study Phase: Phase 1

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

Enrollment Status: Active_not_recruiting

Publish Date: September 04, 2026

Intervention Type: Other

Study Phase: Early Phase 1

RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

Enrollment Status: Suspended

Publish Date: September 04, 2026

Intervention Type: Procedure, Radiation, Drug

Study Drug: Atezolizumab

Study Phase: Phase 2/Phase 3

A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers

Enrollment Status: Active_not_recruiting

Publish Date: September 04, 2026

Intervention Type: Other, Drug

Study Drug: Sinecatechins

Study Phase: Phase 2

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial

Enrollment Status: Terminated

Publish Date: September 04, 2026

Intervention Type: Other, Drug

Study Drug: Aspirin

Study Phase: Phase 3

View 7 Less Clinical Trials

6 Total Publications

Acupuncture for Chronic Radiation-Induced Xerostomia in Head and Neck Cancer: A Multicenter Randomized Clinical Trial.

Journal: JAMA network open

Published: May 13, 2024

View All 6 Publications

Similar Doctors

Expertise in

conditions

Dr. Robert J. Behrens

Hematology Oncology

Expertise in

conditions

Dr. Robert J. Behrens

Hematology Oncology

Referral may be required

Mission Blood + Cancer

411 Laurel St., Suite A300,

Des Moines, IA

(0.1 miles away)

515-247-3970

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Robert Beherns, MD is a medical oncology and hematology physician with Mission Cancer + Blood. Dr. Behrens received a Bachelor of Science degree with distinction in Chemistry from Iowa State University. His medical degree was awarded by the University of Iowa College of Medicine. He completed a residency in Internal Medicine at the Johns Hopkins University / Sinai Hospital in Baltimore, Maryland. Dr. Behrens completed a fellowship at the National Cancer Institute (NCI) in Bethesda, Maryland. He specialized in immuno-therapy of cancer and was protocol chairman of a national breast cancer vaccine trial. Dr. Behrens has been extensively involved in colon, pancreas, and ovarian vaccine trials. Dr. Behrens is highly rated in 89 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Febrile Neutropenia, Agranulocytosis, Bone Marrow Aspiration, and Colonoscopy. Dr. Behrens is currently accepting new patients.

Expertise in

104

conditions

Dr. Thomas R. Buroker

Hematology Oncology

Expertise in

104

conditions

Dr. Thomas R. Buroker

Hematology Oncology

Referral may be required

Mission Blood + Cancer

411 Laurel St., Suite A300,

Des Moines, IA

(0.1 miles away)

515-247-3970

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Dr. Thomas Buroker completed his undergraduate work at The University of Iowa where he graduated in 1964. He went on to graduate from the College of Osteopathy Medical and Surgery (now the Des Moines University). Dr. Buroker completed a residency at the Grace Hospital in Detroit. He completed a fellowship in Medical Oncology at Wayne State University Medical School in Detroit. Dr. Buroker is highly rated in 104 conditions, according to our data. His clinical expertise encompasses Severe Congenital Neutropenia, Lung Cancer, Pleuropulmonary Blastoma, Bone Marrow Aspiration, and Gastrostomy. Dr. Buroker is currently accepting new patients.

Expertise in

conditions

Dr. Daniel M. Buroker

Hematology Oncology

Expertise in

conditions

Dr. Daniel M. Buroker

Hematology Oncology

Referral may be required

Mission Blood + Cancer

411 Laurel St., Suite A300,

Des Moines, IA

(0.1 miles away)

515-247-3970

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Dr. Daniel Buroker is a medical oncologist. He earned his medical degree from the University of Iowa. After medical school, Dr. Buroker completed his residency at the Iowa Methodist Medical Center in Des Moines. Dr. Buroker is highly rated in 73 conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Paget Disease of the Breast, Bone Marrow Aspiration, and Gastrostomy. Dr. Buroker is currently accepting new patients.

VIEW MORE Hematologist Oncologists

Frequently Asked Questions about Dr. Joshua C. Lukenbill

How do I make an appointment with Dr. Joshua C. Lukenbill?

You can book an appointment with Dr. Joshua C. Lukenbill by calling their office at 515-247-3970. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Joshua C. Lukenbill a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Joshua C. Lukenbill is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Joshua C. Lukenbill specialize in?

While Dr. Joshua C. Lukenbill is a Hematology Oncology, they have specific expertise in Lung Cancer, Multiple Myeloma, and Glioma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Joshua C. Lukenbill participate in research or clinical trials?

Yes. Dr. Joshua C. Lukenbill has published 6 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Joshua C. Lukenbill's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Joshua C. Lukenbill accept my insurance?

Dr. Joshua C. Lukenbill accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 515-247-3970 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lukenbill's expertise for a condition

ConditionClose